News

December 2023: Emitech has been chosen among top startups for the competitive M2D2 (The Massachusetts Medical Device Development Center and Bio-tech Incubator) accelerator program. This strategic move connects Emitech to vital expertise and resources, propelling our technology to new heights.

April 2023:  We formed a strategic alliance with CytoDiagnostics, Inc., our partner and manufacturer of components for OpiTest, an electrochemical detection device.

October 2022: The paper “Highly Sensitive Fentanyl Detection Based on Nanoporous Electrochemical Immunosensors” was published in IEEE Sensors Journal. DOI: 10.1109/JSEN.2022.3200591. I. A. Levitsky is a corresponding author.

October 2022: Emitech, Inc. joined MassBio (Massachusetts Biotechnology Council), a community of leaders dedicated to growing the life sciences industry and adding value to the healthcare system.

September 2022: Emitech, Inc. became a member of Mansfield Bio-Incubator, Biotech Entrepreneurship in the Boston area.

August 2022: The National Institute of Health/National Institute on Drug Abuse (NIH/NIDA) awarded Emitech a $2.5MM, three-year, SBIR Phase II Grant for a “Wearable sensor for opioids detection based on electrochemical sensor array integrated with Bluetooth device.”

Quote from Congressman Jake Auchincloss, MA-04 “Emitech’s nanotechnology innovation is important to the future of medicine. This grant will allow them to work on the frontlines of the opioid epidemic in the US with their wearable diagnostic devices.”

September 2020: Emitech, Inc.’s contract “Wearable sensor for opioids detection based on electrochemical sensor array integrated with Bluetooth device” was awarded by a Phase I grant from NIH/NIDA program.